clinical trial · NCT00242307
Efficacy and Safety of Roflumilast in Japanese Patients With Bronchial Asthma (20 to 70 y) (APTA-2217-05)
AstraZeneca·phase3·completed·n = 450
Bronchial AsthmaRoflumilast
brief summary
The aim of the study is to investigate the effect of roflumilast (APTA-2217) on lung function in patients with asthma. Roflumilast will be administered orally once daily. The study duration consists of a baseline period (2 to 4 weeks) and a treatment period (24 weeks). The study will provide further data on safety, tolerability, and effectiveness of roflumilast.
started
May 1, 2004
primary completion
Sep 1, 2006
completion
Jun 1, 2007
last updated
Feb 18, 2026
official title
A Confirmatory Study of APTA-2217 in Adult Patients With Bronchial Asthma (A Placebo-controlled Double-blind Comparative Study)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol